Clinical Trials Logo

Clinical Trial Summary

A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03212599
Study type Observational
Source Johannes Gutenberg University Mainz
Contact
Status Completed
Phase N/A
Start date May 2013
Completion date July 2017

See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Recruiting NCT01934751 - Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction N/A
Recruiting NCT03589118 - Qi Gong as a Method of Craving Reduction in Severe Addict Patients N/A
Terminated NCT02374905 - Testing Interventions to Reduce Alcohol Consumption Among Outpatients in a Dental Setting N/A
Recruiting NCT02643264 - Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction N/A
Not yet recruiting NCT01973127 - Transcranial Magnetic Stimulation in the Treatment of Addiction N/A
Recruiting NCT05895643 - Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? Phase 2
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Terminated NCT02014779 - Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program N/A
Completed NCT02384304 - Guided and Unguided Internet Treatment for Problematic Alcohol Use N/A
Completed NCT05093296 - Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder Phase 2/Phase 3
Terminated NCT03854942 - Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System Phase 1
Terminated NCT03190356 - Soberlink - MAP Outcomes Study Protocol